Over the past 20 years, there has been a major increase in the safety of the blood supply, as
demonstrated by declining rates of posttransfusion infection and reductions in estimated …

Over the past 30 years, it has been demonstrated that removal of white blood cells from
blood components is effective in preventing some adverse reactions such as febrile non …

Recent sequencing efforts have led to estimates of human cytomegalovirus (HCMV)
genome-wide intrahost diversity that rival those of persistent RNA viruses [Renzette N …

BACKGROUND The INTERCEPT Blood System pathogen reduction technology (PRT),
which uses amotosalen and ultraviolet A light treatment (amotosalen/UV‐PRT), inactivates …

Transmission of human cytomegalovirus (CMV) via transfusion (TT‐CMV) may still occur
and remains a challenge in the treatment of immunocompromised CMV‐seronegative …

BACKGROUND: Measures to prevent transfusion‐transmitted cytomegalovirus (TT‐CMV)
infection after hematopoietic stem cell transplantation (HSCT) include transfusion of CMV …

After infection, CMV is latently present in mononuclear cells lifelong. When T lymphocyte
mediated control is lost due to immune suppressive treatment, endogenous CMV replication …

BACKGROUND Red blood cell (RBC) transfusion risks could be reduced if a robust
technology for pathogen inactivation of RBC (PI‐RBCs) were to be approved. MATERIALS …

Background Screening for cytomegalovirus (CMV)-specific antibodies is not routine in some
settings. Thus, transfusion of blood products poses risks for susceptible individuals …

Traditionally, leukoreduction and selection of blood products from seronegative donors have
been used as alternative strategies to reduce the risk of transfusion-transmitted …